Short Bowel Syndrome Market is projected to grow at a 15.9 % CAGR (2023–2030), driven by advances in GLP‑2 therapies like Gattex and apraglutide, which reduce dependence on high-cost parenteral nutrition ranging from US $150,000 to 586,000/year https://www.datamintelligence.com/research-report/short-bowel-syndrome-market?dr